Daniel Von Hoff, M.D., F.A.C.P.

Clinical Development

Dr. Von Hoff has conducted clinical trials on more than 200 antineoplastic and biologic agents including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others.

From 2004-2010, he served in President Bush’s National Cancer Advisory Board. He was formerly president of the American Association for Cancer Research and currently serves as Physician-in-Chief and Distinguished Professor of the Translational Genomics Research Institute where he concentrates on the development of molecular targeted therapies for pancreatic and other advanced cancers.